← Search & browse all drugs
ANTIINFECTIVES FOR SYSTEMIC USE › ANTIVIRALS FOR SYSTEMIC USE › DIRECT ACTING ANTIVIRALS › Antivirals for treatment of HIV infections, combinations
lamivudine, abacavir and dolutegravir
J05AR13
Forms & Strengths
- Film-coated tablets: 300mg lamivudine, 600mg abacavir, 50mg dolutegravir
- Tablets also contain microcrystalline cellulose, magnesium stearate, and povidone
Adult Dosing
- 1 tablet orally once daily
- Can be taken with or without food
- For treatment of HIV-1 infection
Pediatric Dosing
- Safety and efficacy not established for patients less than 12 years of age
- For patients 12 to less than 18 years of age, 1 tablet orally once daily
- Body weight should be at least 40kg
Indications
- Treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older and weighing at least 40kg
- Treatment of HIV-1 infection in combination with other antiretroviral agents
Mechanism of Action
- Lamivudine and abacavir are nucleoside reverse transcriptase inhibitors
- Dolutegravir is an integrase strand transfer inhibitor
- Inhibits replication of HIV-1 by interfering with viral DNA synthesis and integration into host cell genome
Contraindications
- Hypersensitivity to lamivudine, abacavir, or dolutegravir
- Presence of HLA-B*5701 allele, as abacavir is contraindicated in these patients due to risk of hypersensitivity reaction
Adverse Reactions
- Hypersensitivity reactions, including anaphylaxis and Stevens-Johnson syndrome
- Lactic acidosis and severe hepatomegaly with steatosis
- Immune reconstitution syndrome, muscle pain, and insomnia
Drug Interactions
- Do not coadminister with dofetilide, due to increased risk of dofetilide-related adverse reactions
- Coadministration with other medications that contain lamivudine or abacavir is not recommended
- Dolutegravir increases the concentration of metformin, and dose adjustment of metformin may be needed
Curated Content: Needs Vetting Before Put to Clinical Use